drugset / Trial / NCT00097357

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

NCT00097357

Phase 2/3 Completed 1238 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to learn if BMS-562247 can prevent blood clots in the legs and lungs in men and women following unilateral total knee replacement surgery. The safety of this treatment will also be studied.

Timeline

Start
2004-10
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 2.5 mg Oral
Subject Apixaban Small molecule 5 mg Oral
Subject Apixaban Small molecule 10 mg Oral
Subject Apixaban Small molecule 20 mg Oral
Comparator Enoxaparin sodium Other / unclassified 30 mg Subcutaneous
Comparator Warfarin Small molecule 5 mg Oral